Checking insulin resistance in people with multiple system atrophy
Studies insulin resistance and brain scans in adults with multiple system atrophy.
Key facts
- Who runs it
- University Hospital, Bordeaux
- Where
- Bordeaux, FranceSee the site
- Trial code
- Registry title
- Insulin Resistance in Multiple System Atrophy
- Status
- Recruiting
- People taking part
- 124 people, planned
- Started
- 28 Oct 2020
- Expected to end
- 28 Oct 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- Homeostasis Model Assessment of insulin resistance (HOMA)
- MOntreal Cognitive Assessment (MoCA)
- Clinical characteristics of AMS patients
- Brain Magnetic Resonance Imaging (MRI)
- Blood sampling
- Record updated
- 20 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with possible or probable multiple system atrophy (MSA), and for control people without a nerve disease. All must be over 30.
- Age
- Over 30 years
- Sex
- Men and women can join.
- Disease stage
- Patients: possible or probable MSA by the clinical consensus criteria (Gilman et al., 2008). Controls: no neurologic disorder.
- Earlier treatment
- People taking corticosteroids, estrogen, atypical antipsychotics or anti-retroviral agents cannot join.
Main reasons for not taking part
- Diabetes
- Treatment with corticosteroids, estrogen, atypical antipsychotics or anti-retroviral agents
- Any other neurologic disorder
- Pregnancy or breastfeeding
- MOCA score of 21 or lower, or a reason not to have an MRI
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patients :
- Patients suffering from "possible" or "probable" MSA according to clinical consensus criteria (Gilman et al., 2008)
- Age > 30
- Written informed consent
- Patient covered by the national health system; Controls:
- Patients not suffering from a neurologic disorder
- Age > 30
- Written informed consent
- Patient covered by the national health system
Who cannot take part
- Treatment with corticosteroids, estrogen, atypical antipsychotics, and anti-retroviral agents
- Presence of a diabetes
- Any other neurologic disorder
- For patients and controls:
- Patient under tutelage
- Patient unable to give consent
- Pregnancy and breastfeeding
- MOCA ≤21
- Contraindication to perform an MRI
Where in France
- CHU de BordeauxBordeaux, FranceContact: Wassilios MEISSNERTaking people
About the trial
What the trial wants to find out
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder. The pathologic hallmark is the accumulation of aggregated alpha-synuclein in oligodendrocytes forming glial cytoplasmic inclusions. Some symptomatic treatments are available while disease-modification remains an unmet treatment need. Post-mortem findings suggest insulin resistance, i.e. reduced insulin signaling, in the brains of MSA patients. The aim of this study is to complete the target validation of insulin resistance for future treatment trials.
The 2 groups in the trial
- MSA patientTreatment being tested
Patients will be recruited at the French Reference Center for MSA.
Treatment: Homeostasis Model Assessment of insulin resistance (HOMA), MOntreal Cognitive Assessment (MoCA), Clinical characteristics of AMS patients, Brain Magnetic Resonance Imaging (MRI), and Blood sampling
- ControlOther group
Healthy volunteer matched for age (+/- 5years) and sex with MSA patient.
Treatment: Homeostasis Model Assessment of insulin resistance (HOMA), MOntreal Cognitive Assessment (MoCA), Brain Magnetic Resonance Imaging (MRI), and Blood sampling
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Insulin Resistance in Multiple System Atrophy
- Plain-language title
- Checking insulin resistance in people with multiple system atrophyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 July 2025